Patents by Inventor Colin A. Leech

Colin A. Leech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8110399
    Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: February 7, 2012
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
  • Publication number: 20030082155
    Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
    Type: Application
    Filed: April 11, 2002
    Publication date: May 1, 2003
    Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech, Anna Louise Nolan, Andreas Lechner
  • Publication number: 20020164307
    Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and GLP-1 receptor have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby stem cells which express one or both of nestin and GLP-1R can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed.
    Type: Application
    Filed: September 26, 2001
    Publication date: November 7, 2002
    Inventors: Joel F. Habener, Henryk Zulewski, Melissa K. Thomas, Elizabeth J. Abraham, Mario Vallejo, Colin A. Leech